Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)
Press Release
Press Release - Q1FY27
- Revenue 822mn +8.8% y-y; Operating EBITDA 191mn +21.4% y-y (margin 23.2%, +241 bps); PAT 132mn +22.2% y-y (margin 16.0%)
- Strong growth driven by higher MR productivity and brand strength; outperformed industry growth
- Completed acquisition of 85% stake in Aequitas Healthcare; entry into hospital supplies segment
- Cash balance robust at 1700mn despite 400mn buyback; debt-light, cash-rich balance sheet
- Targeting 100+mn EBITDA from Aequitas by year 2 post-integration
- Management confident of sustaining profitable growth and pursuing value-accretive inorganic opportunities
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 JAGSNPHARM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add JAGSNPHARM to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Jagsonpal Pharmaceuticals Limited
Important.
The summary above is generated automatically from Jagsonpal Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.